Literature DB >> 18188642

Risk-stratified management of well-differentiated thyroid cancers: a review of experience from a single institution, 1990-2003.

M H Chew1, G Chan, M M A Siddiqui, B C Tai, R Sivanandan, K C Soo, D T H Lim.   

Abstract

INTRODUCTION: Controversy persists regarding ideal management strategies in well-differentiated thyroid cancers (WDTC). This retrospective study reviews the utilization of a modified AMES risk stratification in the management of our institution's patients.
METHODS: A total of 352 patients (median follow-up of 5.5 years) were reviewed and were risk stratified. Surgical resection was performed, and patients with clinically palpable lymph nodes were subjected to radical neck dissection. Patients were referred for adjuvant therapy if necessary.
RESULTS: Of the 352 patients, 264 (75%) were females and 276 (78%) had papillary thyroid cancer (PTC). For those with lymph nodes (50%), 95% had PTC. In this series, 72% of the patients underwent total thyroidectomy; 5-year disease-free survival probability was 100% in low-risk patients, 92% in intermediate-risk patients, and 64% in high-risk patients. The 5-year overall survival probability was 100% in low-risk patients, 96% in intermediate-risk patients, and 69% in high-risk patients, respectively (both logrank trend p<0.001).
CONCLUSIONS: Management of WDTC requires multimodal treatment and should be based on patient risk classifications. We recommend aggressive surgical resection for all gross disease in high-risk and intermediate-risk patients. Adjuvant therapy is recommended in high-risk patients, but should be individualized for intermediate-risk patients. Total thyroidectomy may not be necessary in low-risk patients.

Entities:  

Mesh:

Year:  2008        PMID: 18188642     DOI: 10.1007/s00268-007-9343-5

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  38 in total

1.  AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology.

Authors:  R H Cobin; H Gharib; D A Bergman; O H Clark; D S Cooper; G H Daniels; R A Dickey; D S Duick; J R Garber; I D Hay; J S Kukora; H M Lando; A B Schorr; M A Zeiger
Journal:  Endocr Pract       Date:  2001 May-Jun       Impact factor: 3.443

2.  Staging in thyroid carcinoma.

Authors:  B Cady
Journal:  Cancer       Date:  1998-09-01       Impact factor: 6.860

3.  A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group.

Authors:  D P Byar; S B Green; P Dor; E D Williams; J Colon; H A van Gilse; M Mayer; R J Sylvester; M van Glabbeke
Journal:  Eur J Cancer       Date:  1979-08       Impact factor: 9.162

4.  The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.

Authors:  R W Tsang; J D Brierley; W J Simpson; T Panzarella; M K Gospodarowicz; S B Sutcliffe
Journal:  Cancer       Date:  1998-01-15       Impact factor: 6.860

5.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

6.  AMES prognostic index and extent of thyroidectomy for well-differentiated thyroid cancer in the United States.

Authors:  Philip I Haigh; David R Urbach; Lorne E Rotstein
Journal:  Surgery       Date:  2004-09       Impact factor: 3.982

7.  The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients.

Authors:  N A Samaan; P N Schultz; R C Hickey; H Goepfert; T P Haynie; D A Johnston; N G Ordonez
Journal:  J Clin Endocrinol Metab       Date:  1992-09       Impact factor: 5.958

8.  Well-differentiated thyroid carcinoma: factors predicting recurrence and survival.

Authors:  L H Y Lim; K C Soo; Y K Chong; F Gao; G S Hong; T H Lim
Journal:  Singapore Med J       Date:  2002-09       Impact factor: 1.858

Review 9.  Radioiodine therapy for thyroid cancer.

Authors:  D C Sweeney; G S Johnston
Journal:  Endocrinol Metab Clin North Am       Date:  1995-12       Impact factor: 4.741

10.  Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma.

Authors:  M E Dottorini; G Lomuscio; L Mazzucchelli; A Vignati; L Colombo
Journal:  J Nucl Med       Date:  1995-01       Impact factor: 10.057

View more
  1 in total

1.  Effects of endocrine therapy on the prognosis of elderly patients after surgery for papillary thyroid carcinoma.

Authors:  Qing Xia; Shuai Dong; Ping-Da Bian; Jue Wang; Cheng-Jiang Li
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-03-06       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.